


Pediatric Protocol Priority Active and Pending Trials

All Sites



PENDING

Pediatric Protocol Priority Active and Pending Trials

All Sites

COG
Randomized
Study of
Electroacupunct
ure Treatment
for Delayed
Chemotherapy-
Induced Nausea
and Vomiting in
Patients with
Pediatric Solid
Tumors (02-AT-
0172)
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100972

COG
Phase II Trial of
Ixabepilone
(BMS-247550),
an Epithilone B
Analog, in
Children and
Young Adults
with Refractory
Solid Tumors
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101017

COG
Establishing
Continuous Cell Lines
and Xenografts
from Pediatric
Cancers for Biological
and
Pre-Clinical
Therapeutic Studies
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 101106

PENDING

Pediatric Protocol Priority Active and Pending Trials

All Sites

COG
A Group-Wide,
Prospective
Study of
Ototoxicity
Assessment in
Children
Receiving
Cisplatin
Chemotherapy.
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101125

COG
A Phase III
Randomized
Trial of GCSF
Stimulated Bone
Marrow vs.
Conventional
Bone Marrow
as a Stem Cell
Source In
Matched Sibling
Donor
Transplantation
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101220

COG
Pharmacokinetic
s of Daunomycin
in Children.
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101126
PENDING

COG
A Phase II Study
of Pemetrexed
in Children with
Recurrent
Malignancies
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101175

PENDING

Pediatric Protocol Priority Active and Pending Trials

Germ Cell

COG
A Phase II Study
to Assess the
Ability of
Neoadjuvant
Chemotherapy
+/- Second Look
Surgery to
Eliminate All
Measurable
Disease Prior to
Radiotherapy for
Non-
Germinomatous
Germ Cell
Tumor (NGGCT)
CTO#100896

COG
A Phase III
Study of
Reduced
Therapy in the
Treatment of
Children with
Low and
Intermediate
Risk Germ Cell
Tumors
CTO#100940

COG
Pilot Study of
Cisplatin,
Etoposide,
Bleomycin and
Escalatin Dose
Cyclophosphami
de Therapy for
Children with
High-Risk
Malignant Germ
Cell Tumors
CTO#100960

Pediatric Protocol Priority Active and Pending Trials

Low Bone Mass

PENDING

Pediatric Protocol Priority Active and Pending Trials

Brain and Nervous System

COG
Phase III
Randomized Study
of Chimeric Antibody
14.18 (Ch 14.18) in
High Risk
Neuroblastome
following
Myeloablative
Therapy and
Autologous Stem
Cell Rescue
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 101157

COG
Neuroblastoma
Biology Studies
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100877

COG
A Phase II Study
of Concurrent
Radiation and
Temozolomide
Followed by
Temozolomide
and CCNU in
the Treatment of
Children with
High Grade
Glioma
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100901

COG
Perinatal
Neuroblastoma:
Expectant
Observation
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100920
PENDING

COG
A Randomized Study of
Purged Versus
Unpurged Peripheral
Blood Stem Cell
Transplant Following
Dose Intensive
Induction Therapy for
High Risk
Neuroblastoma
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 100924

PENDING

Pediatric Protocol Priority Active and Pending Trials

Brain and Nervous System

COG
A Phase II Study
of hu14.18-IL2
Fusion Protein in
Children with
Recurrent or
Refractory
Neuroblastoma
PI: Jacqueline
Kraveka
SC: Rachel
Stroman
CTO# 100930
PENDING

COG
A Children's
Oncology Group
Protocol for
Collecting and
Banking
Pediatric Brain
Tumor Research
Specimens
PI: Jacqueline
Kraveka
SC: Rachel
Stroman
CTO# 100931
PENDING

COG
A Phase III
Randomized Trial of
Intravenous
Gammaglobulin
Therapy for Patients
with Neuroblastoma
Associated
Opsoclonus-
Myoclonus-Ataxia
Syndrome Treated
With Chemotherapy
and Prednisone
PI: Jacqueline
Kraveka
SC: Rachel
Stroman
CTO# 100933
PENDING

COG
A Phase I/II
Study of
Topotecan with
G-CSF and
Radiation
Therapy in
Children with
Malignant
Intrinsic Pontine
Brainstem
Gliomas of
Childhood
PI: Jacqueline
Kraveka
SC: Rachel
Stroman
CTO# 100957
PENDING

COG
A Phase II Study
of Conformal
Radiotherapy in
Patients with
Low-Grade
Gliomas
PI: Jacqueline
Kraveka
SC: Rachel
Stroman
CTO# 100971

PENDING

Pediatric Protocol Priority Active and Pending Trials

Brain and Nervous System

COG
Systemic
Chemotherapy,
Second Look Surgery
and Conformal
Radiation Therapy
Limited to the
Posterior Fossa and
Primary Site for
Children = or > 8 mos
and < 3 years with
Non-Metastatic
Medulloblastoma: A
Children's Oncology
Group Phase III Study
PI: Jacqueline
Kraveka
SC: Rachel Stroman
CTO# 101006
PENDING

COG
A Study Evaluating
Limited Target
Volume Boost
Irradiation and
Reduced Dose
Craniospinal
Radiotherapy
(18.00 Gy) and
Chemotherapy in
Children with
Newly Diagnosed
Standard Risk
Medulloblastoma -
Phase II Double
Randomized
PI: Jacqueline
Kraveka
SC: Rachel
Stroman
CTO# 101011

PENDING

COG
Expanded Access
Protocol for
Purging Blood
Stem Cells or
Bone Marrow from
Patients with High-
Risk
Neuroblastoma
Prior to Autologous
Transplantation
Under FDA
Investigational
Device Exemption
BB-IDE-2259
PI: Jacqueline
Kraveka
SC: Elizabeth
Nista
CTO# 101065

COG
A Phase III
Randomized Trial for
the Treatment of Newly
Diagnosed
Supratentorial PNET
and High Risk
Medulloblastoma in
Children < 36 months
Old With Intensive
Induction
Chemotherapy with
Methotrexate Followed
by Consolidation with
Stem Cell Rescue vs
the Same Therapy
without Methotrexate
PI: Jacqueline
Kraveka
SC: Elizabeth Nista
CTO# 101159

Pediatric Protocol Priority Active and Pending Trials

Brain and Nervous System

COG
Response- and
Biology-Based
Therapy for
Intermediate -risk
Neuroblastoma
SC: Rachel
Stroman
CTO# 101178

COG
Efficacy of
Carboplatin
Administered
Concomitantly
with Radiation
and Isotretinoin
as a Pro-
Apoptotic Agent
in Other Than
Average Risk
Medulloblastom
a/PNET Patients
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101113

MUSC
PBMTC ONC-032 :
High dose
temozolomide,
thiotepa and
carboplatin with
autologous stem cell
rescue (ASCR)
followed by
continuation therapy
with 13-cis-retinoic
acid in patients with
recurrent/refractory
malignant brain
tumors.
PI: Jacqueline
Kravaka
SC: Elizabeth Nista
CTO# 101118

COG
Cilengitide (EMD
121974) (IND#
59073) in
Recurrent or
Progressive and
Refractory
Childhood
High-Grade
Glioma
PI: J. Kravaka
SC: R. Stroman
CTO# 101260
PENDING

PENDING

Pediatric Protocol Priority Active and Pending Trials

Brain and Nervous System

A Phase IIB Study Evaluating the
Efficacy and Safety of Ultratrace
Iobenguane I-131 Among
Patients with Relapsed/
Refractory High-Risk
Neuroblastoma
Protocol NO: MIP-IB-N201
(IND 70,663)
PI: Kravaka
Research Nurse: Carrie Maxwell

CTO#101367
(Program Managed)

PENDING

PENDING

Pediatric Protocol Priority Active and Pending Trials

BMT

COG

A Randomized Double
Blind Placebo Controlled
Clinical Trial to Assess
the Efficacy of Traumeel
S (IND#66649) for the
Prevention and Treatment
of Mucositis in Children
Undergoing
Hematopoietic Stem Cell
Transplantation
PI: Jacqueline Kraveka
SC: Rachel Stroman
CTO# 100935

PENDING

COG

A Randomized Trial of
Sirolimus-Based Graft
versus Host Disease
Prophylaxis after
Hematopoietic Stem
Cell Transplantation in
Relapsed ALL
PI: Jacqueline
Kraveka
SC: Rachel Stroman
CTO# 101110

OSIRIS 275

Expanded access of
prochymal (Exvivo cultured
adult human mesenchymal
stem cells) infusion for the
treatment of Pediatric
patients who have failed to
respond to steroid treatment
for acute GVHD
PI: Hudspeth
SC: Carrie Maxwell
CTO # 101340

PENDING

PENDING

Pediatric Protocol Priority Active and Pending Trials

Extra-Ocular
Retinoblastoma

MUSC
A Trial of
Intensive Multi-
Modality
Therapy for
Extra-Ocular
Retinoblastoma
PI: Jacqueline
Kraceka
SC: Rachel
Stroman
CTO# 101230

PENDING

Pediatric Protocol Priority Active and Pending Trials

Kaposi
Sarcoma

COG
Vincristine,
Dactinomycin, and
Lower Doses of
Cyclophosphamide
with or without
Radiation Therapy for
Patients with Newly
Diagnosed Low-Risk
Embryonal/Botryoid
Rhabdomyosarcoma
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 100879

COG
A Pilot Phase II
Study for
Children with
Infantile
Fibrosarcoma
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100913
PENDING

COG
A Randomized Trial of
the European and
American
Osteosarcoma Study
Group to Optimize
Treatment Strategies
for Resectable
Osteosarcoma Based
on Histological
Response to Pre-
Operative
Chemotherapy
PI: Jacqueline Kravaka
SC: Rachel Stroman
CTO# 100961

PENDING

Pediatric Protocol Priority Active and Pending Trials

Head and Neck

COG
A Study of
Unilateral
Retinoblastoma
With and Without
Histopathologic
High-Risk
Features and the
Role of Adjuvant
Chemotherapy
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100970

COG
Treatment of
Childhood
Nasopharyngeal
Carcinoma with
Neoadjuvant
Chemotherapy and
Concomitant
Chemoradiotherapy
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 100989

PENDING

Pediatric Protocol Priority Active and Pending Trials

Cervical Cancer
Prevention

MUSC
Translating an
Efficacious
Vaccine into the
Control of
Cervical Cancer
PI: Sharon Bond
SC: Kathleen
Cartmell
CTO# 101193
PENDING

PENDING

Pediatric Protocol Priority Active and Pending Trials

High-Risk
Neuroblastoma

COG
Phase II
Randomized
Trial of Single
vs. Tandem
Myeloablative
Consolidation for
High-Risk
Neuroblastoma
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101189

PENDING

Pediatric Protocol Priority Active and Pending Trials

Hodgkins

COG
A Phase III Group-
Wide Study of Dose-
Intensive Response-
Based
Chemotherapy and
Radiation Therapy
for Children and
Adolescents with
Newly Diagnosed
Intermediate Risk
Hodgkin's Disease
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 100951

COG
Treatment of
Children with
Newly-
Diagnosed Low
Stage
Lymphocyte
Predominant
Hodgkin
Disease (LPHD)
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100976

COG
A Phase II Study of
Bortezomib (Velcade,
PS-341, IND #58443)
in Combination with
Ifosfamide/Vinorelbine
in Pediatric Patients
and Young Adults with
Refractory/Recurrent
Hodgkin Disease.
PI: Jacqueline Kravaka
SC: Rachel Stroman
CTO# 101091

COG
Hodgkin Disease
(HD) Banking
Study
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101069

PENDING

Pediatric Protocol Priority Active and Pending Trials

Kidney

COG
Renal Tumors
Classification,
Biology, and
Banking Study
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100999

COG
Treatment of
High Risk Renal
Tumors
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101034
PENDING

COG
Treatment of
Adrenocortical
Tumors with
Surgery plus
lymph Node
Dissection and
Multiagent
Chemotherapy
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101063

COG
Treatment for
Very Low, Low
and Standard
Risk Favorable
Histology Wilms
Tumor
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101076

COG
Treatment of
Newly
Diagnosed
Higher Risk
Favorable
Histology Wilms
Tumors
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101100

PENDING

Pediatric Protocol Priority Active and Pending Trials

Lymphoid Leukemia

COG
Treatment of
Late Isolated
Extramedullary
Relapse from
Acute
Lymphoblastic
Leukemia (ALL)
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100889

COG
High Risk B-
precursor Acute
Lymphoblastic
Leukemia
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100912

COG
Classification of
Acute
Lymphoblastic
Leukemia
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100902

COG
Understanding
the Role of
Adherence and
Ethnic
Differences in
Survival in
Children with
Acute
Lymphoblastic
Leukemia
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100929
PENDING

COG
A Phase III Study of Risk
Directed Therapy for
Infants with Acute
Lymphoblastic Leukemia
(ALL): Randomization of
Highest Risk Infants to
Intensive Chemotherapy
+/- FLT3 Inhibition
(CEP-701, Lestaurtinib;
IND#76431; NSC#
617807)
PI: Jacqueline Kravaka
SC: Rachel Stroman
CTO# 101221

PENDING

Pediatric Protocol Priority Active and Pending Trials

Lymphoid Leukemia

COG
A Childrens
Oncology Group
Protocol for
Collecting and
Banking Relapsed
Acute
Lymphoblastic
Leukemia Research
Specimens
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101062

COG
Intensified
Methotrexate,
Nelarabine (Compound
506U78; IND #52611)
and Augmented BFM
Therapy for Children
and Young Adults with
Newly Diagnosed T-cell
Acute Lymphoblastic
Leukemia
PI: Jacqueline Kravaka
SC: Rachel Stroman
CTO# 101093

COG
Intensive Treatment
for Intermediate-Risk
Relapse of
Childhood B-
Precursor Acute
Lymphoblastic
Leukemia (ALL): A
Randomized Trial of
Vincristine Strategies
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 101111

COG
Impact of Obesity
on the
Pharmacokinetics
of Anticancer
Therapy in
Children with High
Risk Acute
Lymphoblastic
Leukemia (ALL).
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101246

PENDING

Pediatric Protocol Priority Active and Pending Trials

ACLC

PENDING

Pediatric Protocol Priority Active and Pending Trials

Leukemia, Other

COG
A Phase II
Randomized
Trial of
Gemtuzumag
Ozogamicin
(Mylotarg)
Combined with
Conventional
Chemotherapy
for De Novo
Acute Myeloid
Leukemia (AML)
in Children,
Adolescent, and
Young Adults.
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101068

COG
Standard Risk
B-precursor
Acute
Lymphoblastic
Leukemia
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100914

COG
A Study of
Neurocognitive
Function in Children
Treated for ALL: A
Group-wide, Non-
Therapeutic
Companion Study to
AALL0232 and
AALL0434
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 101096

COG
The Treatment of
Down Syndrome
Children with Acute
Myeloid Leukemia
(AML) and
Myelodysplastic
Syndrome (MDS)
Under the Age of 4
Years
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101112

COG
A Feasibility Pilot and
Phase 2 Study of
Chemoimmunotherapy
with Epratuzumab for
Children with
Relapsed CD22-
Positive Acute
Lymphoblastic
Leukemia.
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 101120

PENDING

Pediatric Protocol Priority Active and Pending Trials

Leukemia, Other

COG

Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) and newly diagnosed AML with monosomy 7 or -5/5q- in Children: A Children's Oncology Group(COG) Study
PI: Jacqueline Kraveka
SC: Rachel Stroman
CTO# 101227

Leukemia, Other,
Myeloid and
Monocytic Leukemia

COG

Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients with High Risk Leukemia and Myelodysplasia.
PI: Jacqueline Kraveka
SC: Rachel Stroman
CTO# 101088
PENDING

LYMPHOID
LEUKEMIA

CTO# 101353

Acute Lymphoblastic Leukemia (ALL) Treatment of a named patient under IND290 According to Erwinase Master Treatment Protocol
PI: Hudspeth
SC: Rackoff

PENDING

Pediatric Protocol Priority Active and Pending Trials

Non-Hodgkins Lymphoma

COG
Rare and Cutaneous
Non-Hodgkin
Lymphoma Registry
PI: Jacqueline
Kraveka
SC: Rachel Stroman
CTO# 100928
PENDING

Morgan Stanley Childrens
Hospital New York
Presbyterian
A Phase II Pilot Multicenter
Study of Denileukin Diftitox
Alone and in Combination
with ICE (ICED)
Chemotherapy in Children,
Adolescents and Young
Adults (CAYA) with
Relapsed or Refractory
Anaplastic Large Cell
Lymphoma (CHNY-06-133)
PI: Jacqueline Kraveka
SC: Rachel Stroman
CTO# 101250
PENDING

PENDING

Pediatric Protocol Priority Active and Pending Trials

Non-Hodgkins
Lymphoma

COG
Pharmacokinetics of
Daunomycin in
Children.
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 101126
PENDING

PENDING

Pediatric Protocol Priority Active and Pending Trials

Sarcoma

COG
A Pilot Study of
Low-Dose
Antiangiogenic
Chemotherapy in
Combination with
Standard Multiagent
Chemotherapy for
Patients with Newly
Diagnosed
Metastatic Ewing
Sarcoma Family of
Tumors
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 100934
PENDING

COG
Intensive Multi-Agent
Therapy, Including
Dose-Compressed
Cycles of Ifosfamide/
Etoposide (IE) and
Vincristine/
Doxorubicin/
Cyclophosphamide
(VDC) for Patients
with High-Risk
Rhabdomyosarcoma.
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 101042

COG
Randomized Study
of Vincristine,
Dactinomycin and
Cyclophosphamide
(VAC) versus VAC
Alternating with
Vincristine and
Irinotecan (VI) for
Patients with
Intermediate-Risk
Rhabdomyosarcoma (RMS)
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101080

COG
Risk-Based
Treatment for
Pediatric Non-
Rhabdomyosarcoma
Soft Tissue
Sarcomas (NRSTS)
PI: Jacqueline
Kravaka
SC: Rachel Stroman
CTO# 101099

COG
A Phase II Trial
of Intermediate-
Dose Cytarabine
to Modulate
EWS/FLI for
Children and
Young Adults
with Recurrent
or Refractory
Ewing Sarcoma.
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101127

PENDING

Pediatric Protocol Priority Active and Pending Trials

Sarcoma

COG

A Pilot Study of
Chemotherapy
Intensification by
Adding Vincristine,
Topotecan and
Cyclophosphamide to
Standard
Chemotherapy Agents
with an Interval
Compression Schedule
in Newly Diagnosed
Patients with Localized
Ewing Sarcoma Family
of Tumors.
PI: Jacqueline Kraveka
SC: Rachel Stroman
CTO# 101237

PENDING

Pediatric Protocol Priority Active and Pending Trials

Soft Cell Sarcoma

COG
A Phase II Study of
Trabectedin (ET-743,
YondelisB) in
Children with
Recurrent
Rhabdomyosarcoma,
Ewing Sarcoma, or
Nonrhabdomyosarco
matous Soft Tissue
Sarcoma
PI: Jacqueline
Kraveka
SC: Rachel Stroman
CTO# 101226

COG
A COG Study for
Collecting and
Banking Ewing
Sarcoma Specimens
PI: Jacqueline
Kraveka
SC: Rachel Stroman
CTO# 101228

COG
A Children's
Oncology Group
Protocol for
Collecting and
Banking
Osteosarcoma
Specimens
PI: Jacqueline
Kraveka
SC: Rachel Stroman
CTO# 101229

PENDING

Pediatric Protocol Priority Active and Pending Trials

Sarcoma

COG
Soluble Tumor
Necrosis Factor
Receptor: Enbrel
(Etanercept) for the
Treatment of Acute
Non-Infectious
Pulmonary Dysfunction
(Idiopathic Pneumonia
Syndrome) Following
Allogeneic Stem Cell
Transplantation
PI: Jacqueline Kravaka
SC: Rachel Stroman
CTO# 101237

PENDING

Pediatric Protocol Priority Active and Pending Trials

Recurrent or Resistant
Pediatric Malignant Germ
Cell Tumors

COG
Treatment of
Recurrent or
Resistant
Pediatric
Malignant Germ
Cell Tumors with
Paclitaxel,
Ifosfamide and
Carboplatin
PI: Jacqueline
Kravaka
SC: Rachel
Stroman
CTO# 101190

PENDING

Pediatric Protocol Priority Active and Pending Trials

COG
Collecting and
Banking
Pediatric
Research
Specimens
Including Rare
Pediatric
Tumors.
PI: J. Kravaka
SC: R. Stroman
CTO#101297

COG
Pharmacokinetic-
Pharmacodynamic-
Pharmacogenetic
Study of
Actinomycin-D and
Vincristine in
Children with
Cancer.
SC: Rachel
Stroman
CTO# 101235

COG
Carcinogen
Metabolism, DNA
Repair, Parental
Exposures and
Retinoblastoma
PI: J. Kravaka
SC: R. Stroman
CTO# 101258
PENDING

COG
Umbrella Long-
Term Follow-Up
Protocol
PI: J. Kravaka
SC: R. Stroman
CTO# 101259

PENDING